View Rule

View EO 12866 Meetings Printer-Friendly Version     Download RIN Data in XML

DOJ/DEA RIN: 1117-AB72 Publication ID: Spring 2022 
Title: Changes to a Prescription 

The purpose of this rule is to modify 21 CFR 1306.05(a) to stipulate when pharmacists and/or pharmacist technicians can make changes and/or additions to schedule II-V written controlled substance prescriptions once a prescription has been signed by a DEA registered practitioner.  Currently, 21 CFR 1306.05(a) does not state when or if any changes and/or additions can be made to a controlled substance prescription once a prescription has been signed by a DEA registered practitioner.  This uncertainty can result in delays for patients receiving prescriptions of controlled substances. 

Agency: Department of Justice(DOJ)  Priority: Substantive, Nonsignificant 
RIN Status: Previously published in the Unified Agenda Agenda Stage of Rulemaking: Proposed Rule Stage 
Major: No  Unfunded Mandates: No 
CFR Citation: 21 CFR 1306   
Legal Authority: 21 U.S.C. 821, 827, 871(b)   
Legal Deadline:  None
Action Date FR Cite
NPRM  01/00/2023 
Regulatory Flexibility Analysis Required: No  Government Levels Affected: None 
Small Entities Affected: Businesses  Federalism: No 
Included in the Regulatory Plan: No 
RIN Data Printed in the FR: No 
Agency Contact:
Scott A. Brinks
Section Chief, Regulatory Drafting and Support Section, Diversion Control Division
Department of Justice
Drug Enforcement Administration
8701 Morrissette Drive,
Springfield, VA 22152
Phone:571 362-8209